An Chen

An Chen

Auto-generated profile, based on publicly available information

An Chen

Department of Clinical Biochemistry, Army Medical University, Chongqing 400038, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2024 in Autophagy
Verified
Journal Article
Closed access
YWYaran Wu
Yaran Wu
YCYang Chen
Yang Chen
XYXiaojing Yan
Xiaojing Yan
XDXufang Dai
Xufang Dai
YLYaling Liao
Yaling Liao
JLJiqin Lian
Jiqin Lian

1 May 2005 in Journal of Virology
Verified
Journal Article
Open access
PDF file
ACAn Chen
An Chen
LWLi Wang
Li Wang
JZJingbo Zhang
Jingbo Zhang
ZLZou Liyun
Zou Liyun
ZJZhengcai Jia
Zhengcai Jia
YWYuzhang Wu
Yuzhang Wu
It is necessary to evaluate the cytokine secretion status of CD8+T lymphocytes and elucidate the factors influencing cytokine secretion, because the secretion of cytokines is also an important feature of CD8+T lymphocytes, and the cytokines usually play critical roles in the outcome of diseases. We showed here that peptide AYRPPNAPI, derived from the core antigen of hepatitis B virus (HBV), could bind to H-2 Kdand induce primed splenocytes from HBcAg expression plasmid-immunized mice to produce gamma interferon (IFN-γ) in H-2 Kd- and CD8-dependent manners instead of in a CD4-dependent manner. The induced cells were mainly CD3 and CD8 positive but had no cytotoxic effect on the corresponding target cells. When administered into HBV transgenic mice, these cells can decrease the serum HBV load without causing liver damage. These results suggest that this peptide is a special kind of CD8+T-cell epitope, for which specific CD8+T cells can produce IFN-γ when antigenic stimulation is encountered but which have no cytotoxic effect on the corresponding target cells both in vitro and in HBV transgenic mice. This phenomenon indicates initially that the functional mechanisms of CD8+T cells can be determined by their epitope specificity, which may be associated with the development of epitope-based immunotherapeutic approaches for infectious diseases and tumors.

1 March 2020 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
YDYuan Dong
Yuan Dong
HHHanjin Hou
Hanjin Hou
ACAn Chen
An Chen
WMWei Ma
Wei Ma
MYMoli Yin
Moli Yin
JCJianhui Cai
Jianhui Cai
D-dimer is an essential diagnostic index of thrombotic diseases. Since the existing anti-D-dimer antibodies vary in quality and specificity, a search for alternative anti-D-dimer antibodies is required. The present study aimed to screen a novel monoclonal antibody (mAb) against D-dimer using a light-initiated chemiluminescence assay (LiCA). In this work, mice were immunized with antigen prepared from human plasma by enzyme hydrolysis. After screening, a novel mAb, DD 2G11, was obtained. The results of sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis indicated that DD 2G11 could be used as a standard marker for D-dimer. The isotype of DD 2G11 was IgG1, the Ka value was 0.646 nM-1, and the Kd value was 50 nM, indicating that the binding affinity to D-dimer was very high. Furthermore, no cross-reactivity between DD 2G11 and other fibrinogen degradation products (FgDPs) was found. Finally, the correlation between DD 2G11 and the reference antibody (commercial antibody) was investigated by analyzing 56 clinical samples using a latex-enhanced turbidimetric immunoassay (LTIA). The R2 value of the linear regression was 0.94538, indicating that DD 2G11 met clinical requirements. In conclusion, the present study provides a more expeditious protocol to screen mAbs and provides a clinically usable mAb against D-dimer.

8 July 2025 in Experimental Cell Research
Verified
Journal Article
Closed access
XYXiaojing Yan
Xiaojing Yan
YWYaran Wu
Yaran Wu
XDXufang Dai
Xufang Dai
HWHuizhong Wen
Huizhong Wen
WXWei Xiang
Wei Xiang
JLJiqin Lian
Jiqin Lian